Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 4
1948 1
1949 1
1951 1
1953 1
1954 2
1956 3
1957 3
1958 2
1959 1
1960 3
1961 2
1962 3
1963 3
1964 7
1965 2
1966 2
1967 2
1968 3
1969 3
1970 6
1971 7
1972 5
1973 2
1974 4
1975 13
1976 7
1977 7
1978 8
1979 4
1980 6
1981 7
1982 7
1983 18
1984 13
1985 15
1986 14
1987 11
1988 10
1989 18
1990 28
1991 24
1992 34
1993 25
1994 29
1995 22
1996 23
1997 18
1998 30
1999 29
2000 16
2001 27
2002 35
2003 28
2004 27
2005 31
2006 38
2007 40
2008 34
2009 42
2010 52
2011 70
2012 94
2013 65
2014 64
2015 68
2016 55
2017 33
2018 30
2019 54
2020 53
2021 42
2022 49
2023 62
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

1,508 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Among authors: silverman d. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk.
Silverman DA, Martinez VK, Dougherty PM, Myers JN, Calin GA, Amit M. Silverman DA, et al. Cancer Res. 2021 Mar 15;81(6):1431-1440. doi: 10.1158/0008-5472.CAN-20-2793. Epub 2020 Dec 17. Cancer Res. 2021. PMID: 33334813 Free PMC article. Review.
Loss of p53 drives neuron reprogramming in head and neck cancer.
Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN. Amit M, et al. Among authors: silverman da. Nature. 2020 Feb;578(7795):449-454. doi: 10.1038/s41586-020-1996-3. Epub 2020 Feb 12. Nature. 2020. PMID: 32051587 Free PMC article.
SIX AUTHORS REPLY.
Koutros S, Lubin JH, Graubard BI, Blair A, Beane Freeman LE, Silverman DT. Koutros S, et al. Among authors: silverman dt. Am J Epidemiol. 2020 Apr 2;189(4):361-362. doi: 10.1093/aje/kwz205. Am J Epidemiol. 2020. PMID: 31566210 Free PMC article. No abstract available.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Among authors: silverman d. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, Chang A, Csaky KG, Haskova Z, Lin H, Ruiz CQ, Ruamviboonsuk P, Silverman D, Wykoff CC, Willis JR. Eter N, et al. Among authors: silverman d. Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar. Ophthalmol Sci. 2021. PMID: 36246184 Free PMC article.
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR, Yoon YH, Quezada-Ruiz C. Khanani AM, et al. Among authors: silverman d. Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec. Ophthalmol Sci. 2021. PMID: 36246941 Free PMC article.
Istaroxime in HFpEF: Can We Relax Already?
Tedford RJ, Silverman DN. Tedford RJ, et al. Among authors: silverman dn. JACC Heart Fail. 2023 Jul;11(7):772-774. doi: 10.1016/j.jchf.2023.03.004. Epub 2023 Apr 26. JACC Heart Fail. 2023. PMID: 37115129 Free article. No abstract available.
1,508 results